Continuing or Adding IL-2 in Patients Treated with Antiretroviral Therapy (ACTG Protocol A5051, a Rollover Trial of ACTG Protocol A328)

DSpace/Manakin Repository

Continuing or Adding IL-2 in Patients Treated with Antiretroviral Therapy (ACTG Protocol A5051, a Rollover Trial of ACTG Protocol A328)

Citable link to this page

 

 
Title: Continuing or Adding IL-2 in Patients Treated with Antiretroviral Therapy (ACTG Protocol A5051, a Rollover Trial of ACTG Protocol A328)
Author: Pollard, Richard B; Landay, Alan; Fox, Lawrence; Mitsuyasu, Ronald; Bosch, Ronald J.; Aga, Evgenia

Note: Order does not necessarily reflect citation order of authors.

Citation: Bosch, Ronald J., Richard B. Pollard, Alan Landay, Evgenia Aga, Lawrence Fox, and Ronald Mitsuyasu. 2010. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Research and Therapy 7:30.
Full Text & Related Files:
Abstract: Background: Effective antiretroviral therapy reduces HIV-1 RNA levels, improves CD4 T-cell counts, and lowers the risk of opportunistic infections and malignancies. Interleukin-2 (IL-2) has been shown to increase CD4 T-cell numbers mainly by expanding CD4 cells and by prolonging their half-lives. HIV-infected patients previously enrolled into A328 had been randomized to antiretroviral therapy (ART) alone or ART followed by IL-2. In A5051, 53 patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks; 27 patients who had received ART alone received IL-2 for 80 weeks.Results The patients previously receiving IL-2 continued to have elevated CD4 levels with extended use of IL-2. The prior ART-alone recipients had increases in CD4 levels to comparable levels as the prior IL-2 recipients (median 804 versus 847 cells/mm3 at week 72; 60% versus 9% had >50% increase in A5051 to week 72, p < 0.001). Those who had previously received IL-2 required fewer IL-2 cycles to maintain their CD4 T-cell counts compared to those newly initiating IL-2. The treatments were well tolerated with no significant differences in toxicity or discontinuations between those newly versus previously receiving IL-2. There were few clinical events observed. Conclusions: Although sustained CD4 T-cell count increases were seen with IL-2 administration as in other studies, the absence of clinical benefit in two recent randomized trials has demonstrated no apparent role for IL-2 as a therapy in HIV disease. Trial Registration A5051 ClinicalTrials.gov Identifier: NCT00000923.
Published Version: doi:10.1186/1742-6405-7-30
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924251/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4556389
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters